J.P. Morgan analyst Daniel Kerven maintained a Buy rating on RELX plc (RLXXF – Research Report) today and set a price target of £42.50.
MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related disorders and myopathies announces a ...
For all latest news, follow The Daily Star's Google News channel. The Stanford/Elsevier's Top 2% Scientist Rankings, now in its sixth iteration, lists the world's leading researchers. These ...